Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Functional basis for complement evasion by staphylococcal superantigen-like 7.

Bestebroer J, Aerts PC, Rooijakkers SH, Pandey MK, Köhl J, van Strijp JA, de Haas CJ.

Cell Microbiol. 2010 Oct;12(10):1506-16. doi: 10.1111/j.1462-5822.2010.01486.x.

2.

Full functional activity of SSL7 requires binding of both complement C5 and IgA.

Lorenz N, Clow F, Radcliff FJ, Fraser JD.

Immunol Cell Biol. 2013 Aug;91(7):469-76. doi: 10.1038/icb.2013.28. Epub 2013 Jun 25.

PMID:
23797068
3.

Structural basis for inhibition of complement C5 by the SSL7 protein from Staphylococcus aureus.

Laursen NS, Gordon N, Hermans S, Lorenz N, Jackson N, Wines B, Spillner E, Christensen JB, Jensen M, Fredslund F, Bjerre M, Sottrup-Jensen L, Fraser JD, Andersen GR.

Proc Natl Acad Sci U S A. 2010 Feb 23;107(8):3681-6. doi: 10.1073/pnas.0910565107. Epub 2010 Feb 4.

4.

Structural basis for evasion of IgA immunity by Staphylococcus aureus revealed in the complex of SSL7 with Fc of human IgA1.

Ramsland PA, Willoughby N, Trist HM, Farrugia W, Hogarth PM, Fraser JD, Wines BD.

Proc Natl Acad Sci U S A. 2007 Sep 18;104(38):15051-6. Epub 2007 Sep 11.

5.

The staphylococcal superantigen-like protein 7 binds IgA and complement C5 and inhibits IgA-Fc alpha RI binding and serum killing of bacteria.

Langley R, Wines B, Willoughby N, Basu I, Proft T, Fraser JD.

J Immunol. 2005 Mar 1;174(5):2926-33.

6.

Interaction of human, rat, and mouse immunoglobulin A (IgA) with Staphylococcal superantigen-like 7 (SSL7) decoy protein and leukocyte IgA receptor.

Wines BD, Ramsland PA, Trist HM, Gardam S, Brink R, Fraser JD, Hogarth PM.

J Biol Chem. 2011 Sep 23;286(38):33118-24. doi: 10.1074/jbc.M111.272252. Epub 2011 Jul 22.

7.
8.

Pre-neutralization of C5a-mediated effects by the monoclonal antibody 137-26 reacting with the C5a moiety of native C5 without preventing C5 cleavage.

Fung M, Lu M, Fure H, Sun W, Sun C, Shi NY, Dou Y, Su J, Swanson X, Mollnes TE.

Clin Exp Immunol. 2003 Aug;133(2):160-9.

9.

Staphylococcus aureus metalloprotease aureolysin cleaves complement C3 to mediate immune evasion.

Laarman AJ, Ruyken M, Malone CL, van Strijp JA, Horswill AR, Rooijakkers SH.

J Immunol. 2011 Jun 1;186(11):6445-53. doi: 10.4049/jimmunol.1002948. Epub 2011 Apr 18.

10.

Staphylococcus aureus virulence is enhanced by secreted factors that block innate immune defenses.

Jongerius I, von Köckritz-Blickwede M, Horsburgh MJ, Ruyken M, Nizet V, Rooijakkers SH.

J Innate Immun. 2012;4(3):301-11. doi: 10.1159/000334604. Epub 2012 Feb 7.

11.

Recurrent infections and immune evasion strategies of Staphylococcus aureus.

Kim HK, Thammavongsa V, Schneewind O, Missiakas D.

Curr Opin Microbiol. 2012 Feb;15(1):92-9. doi: 10.1016/j.mib.2011.10.012. Epub 2011 Nov 14. Review.

12.

Immune evasion by staphylococci.

Foster TJ.

Nat Rev Microbiol. 2005 Dec;3(12):948-58. Review.

PMID:
16322743
13.

Hyperglycemia inhibits complement-mediated immunological control of S. aureus in a rat model of peritonitis.

Mauriello CT, Hair PS, Rohn RD, Rister NS, Krishna NK, Cunnion KM.

J Diabetes Res. 2014;2014:762051. doi: 10.1155/2014/762051. Epub 2014 Dec 31.

14.

Staphylococcal complement evasion by various convertase-blocking molecules.

Jongerius I, Köhl J, Pandey MK, Ruyken M, van Kessel KP, van Strijp JA, Rooijakkers SH.

J Exp Med. 2007 Oct 1;204(10):2461-71. Epub 2007 Sep 24.

15.

A Staphylococcus aureus TIR domain protein virulence factor blocks TLR2-mediated NF-κB signaling.

Askarian F, van Sorge NM, Sangvik M, Beasley FC, Henriksen JR, Sollid JU, van Strijp JA, Nizet V, Johannessen M.

J Innate Immun. 2014;6(4):485-98. doi: 10.1159/000357618. Epub 2014 Jan 25.

16.

Differential Interaction of the Staphylococcal Toxins Panton-Valentine Leukocidin and γ-Hemolysin CB with Human C5a Receptors.

Spaan AN, Schiepers A, de Haas CJ, van Hooijdonk DD, Badiou C, Contamin H, Vandenesch F, Lina G, Gerard NP, Gerard C, van Kessel KP, Henry T, van Strijp JA.

J Immunol. 2015 Aug 1;195(3):1034-43. doi: 10.4049/jimmunol.1500604. Epub 2015 Jun 19.

17.

Staphylococcus aureus formyl peptide receptor-like 1 inhibitor (FLIPr) and its homologue FLIPr-like are potent FcγR antagonists that inhibit IgG-mediated effector functions.

Stemerding AM, Köhl J, Pandey MK, Kuipers A, Leusen JH, Boross P, Nederend M, Vidarsson G, Weersink AY, van de Winkel JG, van Kessel KP, van Strijp JA.

J Immunol. 2013 Jul 1;191(1):353-62. doi: 10.4049/jimmunol.1203243. Epub 2013 Jun 5.

18.

Role of complement receptors 1 and 2 (CD35 and CD21), C3, C4, and C5 in survival by mice of Staphylococcus aureus bacteremia.

Cunnion KM, Benjamin DK Jr, Hester CG, Frank MM.

J Lab Clin Med. 2004 Jun;143(6):358-65.

PMID:
15192652
19.

Inhibition of C5a-induced inflammation with preserved C5b-9-mediated bactericidal activity in a human whole blood model of meningococcal sepsis.

Sprong T, Brandtzaeg P, Fung M, Pharo AM, Høiby EA, Michaelsen TE, Aase A, van der Meer JW, van Deuren M, Mollnes TE.

Blood. 2003 Nov 15;102(10):3702-10. Epub 2003 Jul 24.

20.

Role of protein A in the evasion of host adaptive immune responses by Staphylococcus aureus.

Falugi F, Kim HK, Missiakas DM, Schneewind O.

MBio. 2013 Aug 27;4(5):e00575-13. doi: 10.1128/mBio.00575-13.

Supplemental Content

Support Center